ArteraAI Prostate Test – Patient Brochure 2025
For many patients with lower-risk localized prostate cancer, forgoing or delaying definitive therapy through active surveilla [...]
U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced to [...]
Multimodal AI Shows No Evidence of Bias in Prostate...
The study evaluated the performance of a multimodal artificial intelligence model to close gaps in care and validate that AI [...]
Artera Bullish on Prostate Cancer Test Following NYS Approval,...
NEW YORK – Startup firm Artera is continuing to make commercial progress with its artificial intelligence-based prostate canc [...]
AI News: Artera presented data at #ASCO25 showing that...
CMO Tim Showalter describes the finding, which was selected as a "Best of ASCO" oral presentation. Plus, helping to determine [...]
Artera Launches Registry Trial to Measure Real-World Impact and...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced th [...]
Artera Product Webinar – June 2025
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating localized prostate cancer. Watch th [...]
How AI Is Helping Cancer Patients: Saving Lives And...
Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times t [...]